Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Genistein, a naturally occurring isoflavone found primarily in soy products, has attracted scientific interest for its potential neuroprotective effects, including possible benefits in Alzheimer’s Disease (AD). Preclinical studies suggest that genistein may exert protective effects via several mechanisms relevant to AD pathology: it acts as an antioxidant, reduces inflammation, inhibits amyloid-beta aggregation, and modulates estrogen receptors, which are implicated in cognitive function. Some animal studies have shown that genistein supplementation can reduce amyloid plaque formation, improve synaptic function, and mitigate memory impairment in AD models.

However, clinical evidence in humans is limited and inconclusive. A few small-scale clinical trials have explored soy isoflavones (including genistein) and cognitive function in elderly populations, with mixed results—some reporting modest cognitive benefits, while others show no significant effect. A 2020 pilot study indicated that high-dose genistein might slow cognitive decline in early Alzheimer’s, but the sample size was small and further replication is needed.

Overall, while there is a growing body of preclinical data and some early-stage clinical research supporting the potential use of genistein to support cognitive function in AD, the evidence is not yet robust or conclusive. As such, genistein is considered "scientific" in its rationale, but current evidence supporting its use in Alzheimer’s Disease rates as modest (2/5), and additional large-scale, well-controlled human trials are necessary.

More about genistein
More about Alzheimer's Disease

Other ingredients used for Alzheimer's Disease

Other health conditions supported by genistein

Products containing genistein